Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 3 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

330 Multi-omic analysis of TIL therapy in advanced checkpoint-refractory melanoma

  • Elizabeth Park1
  • Bita Sahaf2
  • Amanda Kirane3
  • Gernot Kaber4
  • Hossein Daghagh5
  • Skyler Rietberg5
  • Zinaida Good6
  • Allison Betof7
  • Meelad Amouzgar8
  • Kaitlyn Kim8
  • Brandon J Thong8
  • Claire Billman8
4 more authors
  • Boi Quach8
  • Gaurav Dhapola8
  • Ying Wen Huang9
  • Theodore Roth10
10 affiliations
  1. 12Section of Emergency Medicine, Baylor College of Medicine and Harris Health System, Ben Taub General Hospital Emergency Center, Houston, Texas, USA
  2. 2Cancer Institute, Stanford University School of Medicine, Palo Alto, California, USA
  3. 31Stanford University School of Medicine, Stanford, CA, USA
  4. 48 Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA
  5. 51Stanford Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
  6. 62Stanford Center for Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA, USA
  7. 7Stanford University School of Medicine, Stanford, California, USA
  8. 8Stanford University, Stanford, CA, USA
  9. 9Center for Cancer Cell Therapy, Stanford, CA, USA
  10. 10Stanford University, San Francisco, CA, USA
Open at sourcePDFDOICite

Related

  1. 611 Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing phase 1/2 study
    Andrew Haydon, Jose Lutzky, Siwen Hu-Lieskovan +17
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  2. Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial
    Roxane Riemer, Lukas M. Braun, Sophie Giesler +43
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  3. 147 JAK1- altered checkpoint inhibitor-resistant melanoma treated with intratumoral oncolytic viral therapy: a 2-patient case series
    Khola Khan, Daniel H Johnson
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  4. B cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma
    Kavita M. Dhodapkar, Antonio Matera, Alyssa M. Duffy +6
    The Journal of Clinical InvestigationPeer-reviewedCC BY 4.0Full text2 citedOncologyPMC
  5. Post-ICB Lymphocyte Stability Following Immune Checkpoint Blockade Is Coupled to Mitochondrial Haplotype and Clinical Outcome in Advanced Melanoma
    S. Sun, M. C. Chan, R. A. Watson +14
    medRxivPreprintCC BY-NC-NDFull textOncologymedRxiv

Cite

BibTeXRIS
BibTeX
@article{park2026multiomic,
  title = {{330 Multi-omic analysis of TIL therapy in advanced checkpoint-refractory melanoma}},
  author = {Elizabeth Park and Bita Sahaf and Amanda Kirane and Gernot Kaber and Hossein Daghagh and Skyler Rietberg and Zinaida Good and Allison Betof and Meelad Amouzgar and Kaitlyn Kim and Brandon J Thong and Claire Billman and Boi Quach and Gaurav Dhapola and Ying Wen Huang and Theodore Roth},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0330},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0330},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 330 Multi-omic analysis of TIL therapy in advanced checkpoint-refractory melanoma
AU  - Elizabeth Park
AU  - Bita Sahaf
AU  - Amanda Kirane
AU  - Gernot Kaber
AU  - Hossein Daghagh
AU  - Skyler Rietberg
AU  - Zinaida Good
AU  - Allison Betof
AU  - Meelad Amouzgar
AU  - Kaitlyn Kim
AU  - Brandon J Thong
AU  - Claire Billman
AU  - Boi Quach
AU  - Gaurav Dhapola
AU  - Ying Wen Huang
AU  - Theodore Roth
PY  - 2026
DA  - 2026/11/08
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0330
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0330
SN  - 2051-1426
ER  -